-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28

Benzinga·11/06/2026 14:21:08
Listen to the news
Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.